Methods for diagnosing and treating cancers
This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival.
1. A method for detecting whether a subject has a neoplasia of a tissue type selected from endometrium, kidney, stomach, pancreas, and uterus, comprising:
(a) selecting a subject from a population, wherein the subject is suspected of harboring a neoplasia of a tissue type selected from endometrium, kidney, stomach, pancreas, and uterus;
(b) obtaining a biological sample from said subject; and
(c) detecting in the biological sample a ColoUp2 polypeptide, wherein the ColoUp2 polypeptide is encoded by a nucleic acid sequence that is at least 95% identical to the nucleic acid sequence of SEQ ID NO: 2.
2. The method of claim 1 , wherein the ColoUp2 polypeptide is encoded by a nucleic acid sequence that is at least 98% identical to the nucleic acid sequence of SEQ ID NO: 2.
3. The method of claim 1 , wherein the ColoUp2 polypeptide is encoded by SEQ ID NO: 2.
4. The method of claim 1 , wherein the ColoUp2 polypeptide is encoded by a nucleic acid sequence that hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID NO: 2.
5. The method of claim 1 , wherein the ColoUp2 polypeptide has an amino acid sequence that is at least 95% identical to the amino acid sequence as set forth in SEQ ID NO: 1.
6. The method of claim 1 , wherein the ColoUp2 polypeptide has an amino acid sequence that is at least 95% identical to the amino acid sequence as set forth in SEQ ID NO: 3.
7. The method of claim 1 , wherein said biological sample is selected from whole blood, blood plasma, blood serum, urine, and stool samples.
8. The method of claim 7 , wherein said biological sample is a serum sample.
9. The method of claim 8 , wherein said serum sample is enriched for ColoUp2.
10. The method of claim 1 , wherein the Colo Up2 polypeptide is detected by contacting the biological sample with an antibody that interacts with the ColoUp2 polypeptide.
11. The method of claim 10 , wherein the antibody interacts with an epitope on SEQ ID NO: 1 or a portion thereof.
12. The method of claim 11 , wherein the antibody is detectably labeled.
13. The method of claim 12 , wherein the label is selected from an enzyme, a fluorescent substance, a chemiluminescent substance, a chromophore, a radioactive isotope and a complexing agent.
14. The method of claim 1 , further comprising determining the amount of said ColoUp2 polypeptide in the biological sample.
15. The method of claim 1 , wherein the presence of the ColoUp2 polypeptide aids in determining a therapeutic protocol to be administered to the subject having said neoplasia.
16. The method of claim 1 , wherein said neoplasia is a cancer of a tissue selected from uterus, kidney, stomach, and pancreas.
17. The method of claim 1 , wherein said neoplasia is a metastatic cancer initially arising in a tissue selected from uterus, kidney, stomach, and pancreas.
18. The method of claim 1 , wherein if ColoUp2 is detected in the biological sample in step (c), said method further comprises surgically removing said neoplasia from said subject.
19. The method of claim 1 , wherein if ColoUp2 is detected in the biological sample in step (c), said method further comprises treating said subject with chemotherapy.
20. The method of claim 1 , wherein the subject is suspected of harboring a neoplasia of an endometrium tissue type.
21. The method of claim 1 , wherein the subject is suspected of harboring a neoplasia of a kidney tissue type.
22. The method of claim 1 , wherein the subject is suspected of harboring a neoplasia of a stomach tissue type.
23. The method of claim 1 , wherein the subject is suspected of harboring a neoplasia of a pancreas tissue type.
24. The method of claim 1 , wherein the subject is suspected of harboring a neoplasia of a uterus tissue type.